Proven­tion Bio's di­a­betes drug gains PRIME sta­tus; Avro­bio earns or­phan sta­tus

→ Two days af­ter its J&J li­censed Chron’s dis­ease drug flunked a Phase IIa study, Proven­tion Bio an­nounced its lead drug, PRV-031 (teplizum­ab) for type-1 di­a­betes gained PRIME sta­tus from the EMA. Now in Phase III, the mon­o­clon­al an­ti­body binds to the CD3 T Cell re­cep­tor with the aim of shut­ting down the self-re­ac­tive T cells re­spon­si­ble for type 1 di­a­betes with­out af­fect­ing the rest of the im­mune sys­tem. The drug is de­signed as a way of pre­vent­ing or de­lay­ing the dis­ease. It was orig­i­nal­ly li­censed from Macro­Gen­ics.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER